Genome and Company announces Clinical Trial Collaboration with MSD to evaluate ‘GEN-001’ in combination of KEYTRUDA® (pembrolizumab) in phase 2 clinical trial in biliary tract cancer patients

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!